Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Capital Expenditures (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Capital Expenditures for 6 consecutive years, with -$91000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Capital Expenditures fell 117.6% to -$91000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $421000.0, a 86.51% decrease, with the full-year FY2024 number at $509000.0, down 81.63% from a year prior.
  • Capital Expenditures was -$91000.0 for Q3 2025 at 4D Molecular Therapeutics, down from $66000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $8.2 million in Q2 2022 to a low of -$1.5 million in Q3 2023.
  • A 5-year average of $1.3 million and a median of $631000.0 in 2025 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: surged 30126.92% in 2021, then tumbled 174.95% in 2023.
  • 4D Molecular Therapeutics' Capital Expenditures stood at $7.8 million in 2021, then plummeted by 86.0% to $1.1 million in 2022, then skyrocketed by 121.96% to $2.4 million in 2023, then tumbled by 107.63% to -$185000.0 in 2024, then soared by 50.81% to -$91000.0 in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Capital Expenditures are -$91000.0 (Q3 2025), $66000.0 (Q2 2025), and $631000.0 (Q1 2025).